Bio-Path (NASDAQ:BPTH) Now Covered by Analysts at StockNews.com
StockNews.com began coverage on shares of Bio-Path (NASDAQ:BPTH – Free Report) in a research note issued to investors on Saturday. The firm issued a sell rating on the stock. Bio-Path Price Performance Shares of NASDAQ BPTH opened at $0.80 on Friday. Bio-Path has a 12-month low of $0.61 and a 12-month high of $12.37. The […]
More Stories
FY2025 EPS Estimates for Extendicare Increased by Analyst
Extendicare Inc. (TSE:EXE – Free Report) – Equities researchers at Leede Financial upped their FY2025 earnings per share estimates for...
FY2025 EPS Estimates for Extendicare Increased by Analyst
Extendicare Inc. (TSE:EXE – Free Report) – Equities researchers at Leede Financial upped their FY2025 earnings per share estimates for...
FY2025 EPS Estimates for Extendicare Increased by Analyst
Extendicare Inc. (TSE:EXE – Free Report) – Equities researchers at Leede Financial upped their FY2025 earnings per share estimates for...
FY2026 EPS Estimates for Precigen Decreased by HC Wainwright
Precigen, Inc. (NASDAQ:PGEN – Free Report) – Research analysts at HC Wainwright reduced their FY2026 earnings per share estimates for...
FY2026 EPS Estimates for Precigen Decreased by HC Wainwright
Precigen, Inc. (NASDAQ:PGEN – Free Report) – Research analysts at HC Wainwright reduced their FY2026 earnings per share estimates for...
FY2026 EPS Estimates for Precigen Decreased by HC Wainwright
Precigen, Inc. (NASDAQ:PGEN – Free Report) – Research analysts at HC Wainwright reduced their FY2026 earnings per share estimates for...